Sagen Zac‐Varghese

Diabetes and the kidney

Sagen Zac‐Varghese

Diabetic kidney disease (DKD) management has become increasingly complex. For non-specialists in diabetes or kidney disease, there are some basic standards of care that apply to all people with DKD. These include blood glucose optimisation, blood pressure management, renin-angiotensin-aldosterone system inhibitors (RAASi), …

gb (code pays fourni par la source)

Association of British Clinical Diabetologists and UK Kidney Association Joint Clinical Practice Guidelines for the Pharmacological Management of Hyperglycemia in Adults With Type 2 Diabetes Mellitus and CKD

Janaka Karalliedde, Kieran McCafferty, Peter Winocour, Tahseen A Chowdhury et autres

A growing and significant number of people with diabetes develop chronic kidney disease (CKD), and diabetes-related CKD is a leading cause of end-stage kidney disease (ESKD). People with diabetes and CKD have high morbidity and mortality, predominantly related to cardiovascular disease (CVD). …

gb (code pays fourni par la source)

What's new in the management of diabetic kidney disease

Sagen Zac‐Varghese

Diabetic kidney disease (DKD) management is a rapidly evolving field. Alongside risk prediction tools, such as the Kidney Failure Risk Equation, there is greater emphasis on person-centred care and education. For people with type 2 diabetes (T2DM), sodium-glucose cotransporter 2 inhibitors (SGLTi) …

gb (code pays fourni par la source)

Finerenone in the management of diabetes kidney disease

Parijat De, May Thin Khine, Andrew Frankel, Gabrielle Goldet et autres

People with type 2 diabetes are at risk of developing progressive diabetic kidney disease (DKD) and end stage kidney failure. Hypertension is a major, reversible risk factor in people with diabetes for development of albuminuria, impaired kidney function, end-stage kidney disease and …

gb (code pays fourni par la source)

Current management of chronic kidney disease in type‐2 diabetes—A tiered approach: An overview of the joint Association of British Clinical Diabetologists and UK Kidney Association ( ABCD ‐ UKKA ) guidelines

Indranil Dasgupta, Sagen Zac‐Varghese, Khuram Chaudhry, Kieran McCafferty et autres

A growing and significant number of people with diabetes develop chronic kidney disease (CKD). Diabetes-related CKD is a leading cause of end-stage kidney disease (ESKD) and people with diabetes and CKD have high morbidity and mortality, predominantly related to cardiovascular disease (CVD). …

gb (code pays fourni par la source)

Clinical practice guideline for the management of lipids in adults with diabetic kidney disease: abbreviated summary of the Joint Association of British Clinical Diabetologists and UK Kidney Association (ABCD-UKKA) Guideline 2024

Sagen Zac‐Varghese, Patrick B. Mark, Steve Baín, Debasish Banerjee et autres

The contribution of chronic kidney disease (CKD) towards the risk of developing cardiovascular disease (CVD) is magnified with co-existing type 1 or type 2 diabetes. Lipids are a modifiable risk factor and good lipid management offers improved outcomes for people with diabetic …

gb (code pays fourni par la source)

Gene expression signature predicts rate of type 1 diabetes progression

Tomi Suomi, Inna Starskaia, Ubaid Ullah, Omid Rasool et autres

BACKGROUND: Type 1 diabetes is a complex heterogenous autoimmune disease without therapeutic interventions available to prevent or reverse the disease. This study aimed to identify transcriptional changes associated with the disease progression in patients with recent-onset type 1 diabetes. METHODS: Whole-blood samples …

fi, dk, gb, be, us, de (code pays fourni par la source)

Primary amenorrhea? Cause

Sagen Zac‐Varghese

Searchable abstracts of presentations at key conferences in endocrinology ISSN 1470-3947 (print) | ISSN 1479-6848 (online)

A case series of diabetic ketoacidosis associated with SGLT2 inhibitors

Sagen Zac‐Varghese, Sunitha Mathew, Daniel Go, Peter Winocour

Abstract Sodium‐glucose cotransporter 2 inhibitors (SGLT2i) are increasingly initiated as treatment for type 2 diabetes due to favourable cardiorenal characteristics. However, studies have identified an increased risk of diabetic ketoacidosis (DKA). We carried out a retrospective, case‐based study at East and North …

gb (code pays fourni par la source)

Managing type 1 diabetes in frailty

Sagen Zac‐Varghese, Bev Summerhayes, Peter Winocour

Managing type 1 diabetes in frail elderly people can be logistically challenging, particularly for those living alone. District nurse visits are unpredictable and coincide poorly with meal time insulin regimes. Elderly people, particularly those with dementia, have variable oral intake and activity. …

gb (code pays fourni par la source)

Strategies for the Management of Type 2 Diabetes

Peter Winocour, Sagen Zac‐Varghese

Abstract The approach to the management of hyperglycaemia in type 2 diabetes has become increasingly complex with a widening armamentarium of available antihyperglycaemic agents. It is well recognized that several agents have additional benefits (outside of glucose control), for example, on weight …

Clinical practice guidelines for management of hyperglycaemia in adults with diabetic kidney disease

Janaka Karalliedde, Peter Winocour, Tahseen A Chowdhury, Parijat De et autres

A significant percentage of people with diabetes develop chronic kidney disease and diabetes is also a leading cause of end-stage kidney disease (ESKD). The term diabetic kidney disease (DKD) includes both diabetic nephropathy (DN) and diabetes mellitus and chronic kidney disease (DM …

gb (code pays fourni par la source)